In January-June 2011, the company posted sales of RON22.9 million.
Retrasib said its net profit fell 64% on the year to RON0.34 million, from RON0.95 million in the year-ago period, as revenues rose slower than expenses.
Total revenue increased 4% on the year to RON20.5 million in the first six months, while overall costs rose 8% to RON20.1 million.
Retrasib is 80.32%-owned by brothers Octavian and Calin Buzoianu.
On August 1, Retrasib closed up 0.71% at RON0.155 a share in Bucharest. (EUR1=RON4.5364)